High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects - Sorbonne Université
Journal Articles Revue Neurologique Year : 2022

High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects

Nicolas Villain
  • Function : Author
  • PersonId : 1133683
CHU Pitié-Salpêtrière [AP-HP]
V. Planche
  • Function : Author
R. Levy
  • Function : Author

Domains

Psychiatrics and mental health
Fichier principal
Vignette du fichier
Villain2022_Part1.pdf (1.71 Mo) Télécharger le fichier
Origin Publisher files allowed on an open archive

Nicolas VILLAIN  : Connect in order to contact the contributor

https://hal.sorbonne-universite.fr/hal-03797247

Submitted on : Tuesday, October 4, 2022-4:26:56 PM

Last modification on : Monday, April 15, 2024-9:44:19 AM

Long-term archiving on : Thursday, January 5, 2023-7:37:34 PM

Download

Dates and versions

hal-03797247 , version 1 (04-10-2022)

Identifiers

Cite

Nicolas Villain, V. Planche, R. Levy. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects. Revue Neurologique, 2022, ⟨10.1016/j.neurol.2022.06.012⟩. ⟨hal-03797247⟩

Export

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

SORBONNE-UNIVERSITE SU-MEDECINE
10 View
215 Download

Altmetric

Share

More